Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8969916 | 1.00 | PEPD (0.41) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL8969423 | 1.00 | PEPD (0.41) | PEPDMEN1BLMKMT2AACE | |
| Hydrochloric Acid SCHEMBL8970160 | 0.98 | PEPD (0.44) | PEPDMEN1BLMKMT2AACE | |
| Hydrochloric Acid SCHEMBL8970089 | 0.98 | PEPD (0.44) | PEPDMEN1BLMKMT2AACE | |
| SCHEMBL8072246 | 0.95 | CYP2C19 (0.39) | PEPDMEN1BLMKMT2ACYP2C19 | |
| SCHEMBL8970243 | 0.95 | CYP2C19 (0.39) | PEPDMEN1BLMKMT2ACYP2C19 | |
| SCHEMBL8970358 | 0.93 | CYP2C19 (0.38) | PEPDMEN1BLMKMT2ACYP2C19 | |
| Hydrochloric Acid SCHEMBL8970750 | 0.93 | PEPD (0.39) | PEPDMEN1BLMKMT2ACYP2C19 | |
| SCHEMBL8969963 | 0.93 | CYP2C19 (0.38) | PEPDMEN1BLMKMT2ACYP2C19 | |
| SCHEMBL10998711 | 0.85 | ACE (0.38) | PEPDMEN1BLMKMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541804-B1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2025-01-22 | — | — | EP | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3541804-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093577-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-0758013-B1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL CO LTD (JP) | 2000-10-11 | — | — | EP | disclosed |
| US-5855971-A | Liquid crystalline optical film, compensating film for liquid crystal display comprising the liquid crystalline optical film, and liquid crystal display having the compensating film | NIPPON OIL COMPANY, LIMITED (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0758013-A1 | Liquid crystalline optical film, compensating film for liquid crystal display and liquid crystal display | NIPPON OIL COMPANY, LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
| EP-0376294-B1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI LTD (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5370821-A | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-06 | — | — | US | disclosed |
| US-5269965-A | Optically active compounds, liquid crystal compositions comprising said compounds and liquid crystal optical modulators using said compositions | TAKEDA CHEMICAL INDUSTRIES (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0376294-A1 | Optically active compounds, liquid crystal compositions comprising said compounds, and liquid crystal optical modulators using said compositions | HITACHI, LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | PEPD 1936/4885MEN1 4578/4885BLM 3697/4885 |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | PEPD 1936/4885MEN1 4578/4885BLM 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.